Business Context and Reporting Period
Company: Caris Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2025
Reporting Period: Single event date (October 30, 2025)
This filing reports a corporate governance action taken by the Board of Directors regarding the amendment of the Company's Bylaws. It does not contain periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance and does not include financial statements or performance metrics.
Material Changes
Amendment to Bylaws: On October 30, 2025, the Board approved an amendment and restatement of the Company's Bylaws. The primary change establishes a new ownership threshold for derivative proceedings.
- New Requirement: A shareholder (or group acting together) must beneficially own at least 3% of the Company's outstanding shares of common stock at the time a derivative proceeding is instituted.
- Scope: This requirement applies to instituting or maintaining a derivative proceeding.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no management commentary regarding business outlook, guidance, or operational strategy.
Risks and Contingencies: The filing does not disclose new material risks, contingencies, or unusual items beyond the procedural change to shareholder rights. The amendment is intended to modify the rights of security holders regarding derivative litigation.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Bylaws (Exhibit 3.1) to confirm the exact legal language of the 3% ownership threshold.
- Confirm the effective date of the Bylaw amendment relative to the Board approval date of October 30, 2025.
- Review the Company's most recent 10-K or 10-Q filings for current financial performance, as this 8-K contains no financial data.
- Assess the potential impact of the 3% threshold on shareholder activism and derivative litigation risks.